The disclosure relates to norpsilocin compounds, compositions containing those crystalline compounds, and methods of treatment using them. The norpsilocin compounds include crystalline 4-hydroxy-N-methyltryptamine (“crystalline 4-HO-NMT” or “crystalline norpsilocin freebase”), crystalline 4-hydroxy-N-methyltryptammonium fumarate (“crystalline norpsilocin fumarate”), and 4-hydroxy-N-methyltryptammonium fumarate (“norpsilocin fumarate”) and their compositions and uses.

The disclosure relates to norpsilocin compounds, compositions containing those crystalline compounds, and methods of treatment using them. The norpsilocin compounds include crystalline 4-hydroxy-N-methyltryptamine (“crystalline 4-HO-NMT” or “crystalline norpsilocin freebase”), crystalline 4-hydroxy-N-methyltryptammonium fumarate (“crystalline norpsilocin fumarate”), and 4-hydroxy-N-methyltryptammonium fumarate (“norpsilocin fumarate”) and their compositions and uses.

Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

The present disclosure discloses free form or base and salts of compound of formula (I). Said salts include adipate, benzenesulphonate, hydrobromide, fumarate, benzoate, methanesulfonate, L-malate, d-glyconate, sorbate, phosphate, sulfate, L-tartrate, p-methylbenzenesulphonate, citrate, hydrochloride, ethanesulfonate, 1-hydroxy-2-naphthoate, succinate, acetate, glutarate or L-pyroglutamate. The present disclosure also discloses the crystals of free form and above salts.

The present disclosure discloses free form or base and salts of compound of formula (I). Said salts include adipate, benzenesulphonate, hydrobromide, fumarate, benzoate, methanesulfonate, L-malate, d-glyconate, sorbate, phosphate, sulfate, L-tartrate, p-methylbenzenesulphonate, citrate, hydrochloride, ethanesulfonate, 1-hydroxy-2-naphthoate, succinate, acetate, glutarate or L-pyroglutamate. The present disclosure also discloses the crystals of free form and above salts.

A method of obtaining a complex acidic salt of a divalent metal and a dicarboxylic acid includes heating water in a reactor; adding a dicarboxylic acid to the heated water; stirring the water to dissolve the dicarboxylic acid in the heated water to produce a solution or a suspension of the dicarboxylic acid in the heated water; adding MeO to the solution or the suspension, where Me is a divalent metal; continuing the stirring of the solution or suspension until formation of the complex acidic salt Me(AcH).sub.2.nH.sub.2O begins, where Ac is an anion of the dicarboxylic acid, and n=0-8; cooling the complex acidic salt to below a temperature of crystallization; sedimenting the complex acidic salt; filtering the complex acidic salt to remove water from the complex acidic salt; and drying the complex acidic salt.

A method of obtaining a complex acidic salt of a divalent metal and a dicarboxylic acid includes heating water in a reactor; adding a dicarboxylic acid to the heated water; stirring the water to dissolve the dicarboxylic acid in the heated water to produce a solution or a suspension of the dicarboxylic acid in the heated water; adding MeO to the solution or the suspension, where Me is a divalent metal; continuing the stirring of the solution or suspension until formation of the complex acidic salt Me(AcH).sub.2.nH.sub.2O begins, where Ac is an anion of the dicarboxylic acid, and n=0-8; cooling the complex acidic salt to below a temperature of crystallization; sedimenting the complex acidic salt; filtering the complex acidic salt to remove water from the complex acidic salt; and drying the complex acidic salt.

The present invention relates to a synthesis method of preventing the formation of impurities and byproducts in the synthesis of tenofovir disoproxil fumarate (Teno-DF) used as a medicine for hepatitis B and HIV treatment due to its function to promote bioactivities. In the synthesis method of the present invention, an ion-exchange resin (Dowex 50W hydrogen form, sulfonic acidic cation exchange resin) is used to enhance the yield and purity of the compound. The present invention also relates to a method of preparing an oral dissolving film dosage form in the manufacture of a medicine using the tenofovir compound with high purity obtained by the synthesis method of the present invention as an effective ingredient.

The present invention discloses a polyvalent metal ion compound salt of N,N-dimethylglycine and organic acid or a solvate thereof, and use thereof in preparing novel feed additives and feed; the present invention also discloses a composition comprising the polyvalent metal ion compound salt of N,N-dimethylglycine and organic acid or the solvate thereof. The polyvalent metal ion compound salt of N,N-dimethylglycine and organic acid or the solvate thereof provided by the present invention has improvement effect on animal product performance such as improving animal weight gain and reducing feed conversion ratio, showing effects similar to or higher than that of sodium N,N-dimethylglycinate.